Related Experiment Video
Updated: Aug 15, 2026

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
Published on: April 18, 2011
Tolerability and pharmacokinetics of remoxipride after intramuscular administration
1Centre Hospitalier Regional de Nancy, Psychologie Medicale et Psychotherapie Hôpital Jeanne D'Arc, Toul, France.
Abstract:
A study was undertaken in seven schizophrenic patients to evaluate the tolerability and examine the pharmacokinetics of intramuscularly administered remoxipride after a single 200 mg dose and at steady state following repeated doses of 200 mg twice daily for one week. Comparisons of AUC, t1/2 and tmax using the Wilcoxon's signed rank test showed no significant difference between single dose and steady state indicating that the pharmacokinetics of intramuscular remoxipride were linear. The steady-state Cmax was found to be significantly larger than that after single dose and the increase was accounted for by the predicted accumulation factor, assuming linear kinetics. Although the inter-individual variability in plasma concentrations was large, the intra-individual variability was low as shown by the reproducibility of the single-dose and steady-state plasma curves. Remoxipride, administered intramuscularly, was well tolerated.
Related Concept Videos
Routes of Drug Administration: Parenteral
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
Cholinergic Antagonists: Pharmacokinetics
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Modified-Release Drug Delivery Systems: Bioavailability

